The "hurry up and wait" goes on at Abbott Labs (NYSE: ABT )
, as it does at many other large med-tech companies, but Abbott is at
least showing some growth momentum and the comps for the second half of
the year should lead to better reported results. Abbott has also been
busying on the M&A front, recently announcing a deal with Mylan (NASDAQ: MYL )
that shifts the company's Established Pharmaceuticals business firmly
toward faster-growing emerging markets. What the company will do about
its device business is still an open question and how management
addresses it will be something to watch for the remainder of the year.
Please read the full article here:
Abbott Labs Stock Earnings: Why Steady Isn't Enough
No comments:
Post a Comment